X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
October 8, 2026
Cannabics Pharmaceuticals’ Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice
June 28, 2021
Related Post
-
-
Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
October 8, 2026
-
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
October 7, 2026
-
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
October 6, 2026